Sinco Pharmaceuticals Holdings Limited Stock

Equities

6833

KYG8154Y1052

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:09:13 2024-04-23 am EDT 5-day change 1st Jan Change
0.245 HKD 0.00% Intraday chart for Sinco Pharmaceuticals Holdings Limited 0.00% +2.08%

Financials

Sales 2021 2.02B 279M 2.19B Sales 2022 2.27B 313M 2.46B Capitalization 476M 65.66M 515M
Net income 2021 135M 18.63M 146M Net income 2022 69M 9.52M 74.62M EV / Sales 2021 1.42 x
Net Debt 2021 14.9M 2.06M 16.11M Net cash position 2022 137M 18.87M 148M EV / Sales 2022 0.15 x
P/E ratio 2021
19.8 x
P/E ratio 2022
6.88 x
Employees 278
Yield 2021 *
-
Yield 2022
3.7%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments MT
Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director CI
Sinco Pharmaceuticals Warns of Lower 2023 Profit MT
Sinco Pharmaceuticals Holdings Limited Provides Consolidated Earning Guidance for the Year Ended 31 December 2023 CI
Sinco Pharmaceuticals Holdings Limited(SEHK:6833) dropped from S&P Global BMI Index CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sinco Pharmaceuticals Warns of 68% Drop in H1 Profit MT
Sinco Pharmaceuticals Holdings Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 CI
Sinco Pharma Taps Moore Advisory Services for Internal Control Review MT
Sinco Pharmaceuticals Co-CEO Resigns; Shares Slip 3% MT
Sinco Pharmaceuticals Holdings Limited Announces Final Dividend for the Year Ended 31 December 2022, Payable on June 15, 2023 CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sinco Pharmaceuticals Holdings Limited Announces Chief Executive Officer Changes CI
More news
Current month-5.77%
1 month-7.55%
3 months-3.92%
6 months-9.26%
Current year+2.08%
More quotes
1 week
0.23
Extreme 0.23
0.27
1 month
0.23
Extreme 0.23
0.28
Current year
0.21
Extreme 0.213
0.30
1 year
0.21
Extreme 0.213
0.42
3 years
0.18
Extreme 0.183
2.32
5 years
0.16
Extreme 0.161
2.32
10 years
0.15
Extreme 0.146
2.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 20-11-05
Founder 59 11-03-31
Director of Finance/CFO 45 15-01-31
Members of the board TitleAgeSince
Director/Board Member 51 18-11-07
Director/Board Member 87 16-01-31
Founder 59 11-03-31
More insiders
Date Price Change Volume
24-04-23 0.245 0.00% 0
24-04-22 0.245 0.00% 0
24-04-19 0.245 -2.00% 20,000
24-04-18 0.25 0.00% 0
24-04-17 0.25 +2.04% 200,000

Delayed Quote Hong Kong S.E., April 23, 2024 at 04:09 am EDT

More quotes
Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.
More about the company